| 2019 | | Differences in Expression of Human Leukocyte Antigen Class II Subtypes and T Cell Subsets in Behcet's Disease with Arthritis | 김현아, 서창희, 손성향, 정주양 |
| 2015 | | Direct chemotherapeutic dual drug delivery through intra-articular injection for synergistic enhancement of rheumatoid arthritis treatment. | 민병현 |
| 2021 | | Effectiveness and safety of biologic and targeted synthetic disease-modifying anti-rheumatic drugs in elderly patients with rheumatoid arthritis: Real-world data from the KOBIO registry | 김현아 |
| 2023 | | Effects of a self-determination theory-based physical activity programme for postmenopausal women with rheumatoid arthritis: A randomized controlled trial | 김춘자, 안정아 |
| 2022 | | Effects of RETN polymorphisms on treatment response in rheumatoid arthritis patients receiving TNF-α inhibitors and utilization of machine-learning algorithms | 김현아, 정주양 |
| 2023 | | Efficacy and drug retention of tofacitinib in rheumatoid arthritis: from the nationwide Korean College of Rheumatology Biologics registry | 김지원, 김현아, 서창희, 정주양 |
| 2017 | | Efficacy and Safety of Switching from Innovator Rituximab to Biosimilar CT-P10 Compared with Continued Treatment with CT-P10: Results of a 56-Week Open-Label Study in Patients with Rheumatoid Arthritis | 서창희 |
| 2019 | | Efficacy and safety of switching from rituximab to biosimilar CT-P10 in rheumatoid arthritis: 72-week data from a randomized Phase 3 trial | 서창희 |
| 2017 | | Efficacy, Safety and Pharmacokinetics of Up to Two Courses of the Rituximab Biosimilar CT-P10 Versus Innovator Rituximab in Patients with Rheumatoid Arthritis: Results up to Week 72 of a Phase I Randomized Controlled Trial | 서창희 |
| 2019 | | Evaluation of factors affecting the levels of physical activity in patients with rheumatoid arthritis: a cross-sectional study | 부선주, 서창희, 정주양 |
| 2022 | | Factors affecting quality of life in patients with rheumatoid arthritis in South Korea: a cross-sectional study | 김지원, 부선주, 서창희 |
| 2018 | | Factors associated with quality of life and functional disability among rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs for at least 6 months | 서창희 |
| 2021 | | Four-year follow-up of atherogenicity in rheumatoid arthritis patients: from the nationwide Korean College of Rheumatology Biologics Registry | 김현아 |
| 2015 | | High-density genotyping of immune loci in Koreans and Europeans identifies eight new rheumatoid arthritis risk loci. | 서창희 |
| 2017 | | Highly Expression of CD11b and CD32 on Peripheral Blood Mononuclear Cells from Patients with Adult-Onset Still's Disease | 김현아, 서창희, 손성향, 정주양 |
| 2020 | | Impact of immunogenicity on efficacy and tolerability of tumour necrosis factor inhibitors: pooled analysis of biosimilar studies in rheumatoid arthritis | 서창희 |
| 2016 | | Imputing Variants in HLA-DR Beta Genes Reveals That HLA-DRB1 Is Solely Associated with Rheumatoid Arthritis and Systemic Lupus Erythematosus | 서창희 |
| 2019 | | Injectable Click-Crosslinked Hyaluronic Acid Depot To Prolong Therapeutic Activity in Articular Joints Affected by Rheumatoid Arthritis | 민병현 |
| 2017 | | Knowledge and perception of cardiovascular disease risk among patients with rheumatoid arthritis | 부선주, 서창희 |
| 2012 | | Korean Observational Study Network for Arthritis (KORONA): establishment of a prospective multicenter cohort for rheumatoid arthritis in South Korea | 김현아, 서창희 |
| 2010 | | Linkage and association studies of joint morbidity from rheumatoid arthritis. | 민경복 |
| 2019 | | Long-Term Efficacy and Safety of Biosimilar CT-P10 Versus Innovator Rituximab in Rheumatoid Arthritis: 48-Week Results from a Randomized Phase III Trial | 서창희 |
| 2019 | | Long-term efficacy, safety and immunogenicity in patients with rheumatoid arthritis continuing on an etanercept biosimilar (LBEC0101) or switching from reference etanercept to LBEC0101: an open-label extension of a phase III multicentre, randomised, double-blind, parallel-group study | 서창희 |
| 2019 | | Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio are associated with disease activity in polymyalgia rheumatica | 김현아, 서창희, 정주양 |
| 2016 | | Perceived and actual risk of cardiovascular disease in patients with rheumatoid arthritis in Korea: A cross-sectional study | 부선주, 서창희, 정주양 |
| 2014 | | Poor agreement between QuantiFERON-TB Gold test and tuberculin skin test results for the diagnosis of latent tuberculosis infection in rheumatoid arthritis patients and healthy controls. | 김현아, 서창희 |
| 2020 | | Preclinical rheumatoid arthritis and rheumatoid arthritis prevention | 김현아 |
| 2023 | | Predicting physical activity and sarcopenia-related health outcomes in women with rheumatoid arthritis: A test of the self-determination theory | 김춘자, 정주양 |
| 2021 | | Real-world observational study of biosimilars in inflammatory arthritis treatment: a systematic literature review | 김지원, 서창희, 정주양 |
| 2023 | | Retention Rate and Safety of Biologic and Targeted Synthetic DMARDs in Patients with RA-Associated Interstitial Lung Disease: A KOBIO Registry Study | 김지원, 김현아, 서창희, 정주양 |
| 2020 | | Retention Rate and Safety of Biosimilar CT-P13 in Rheumatoid Arthritis: Data from the Korean College of Rheumatology Biologics Registry | 김현아 |
| 2015 | | Rheumatoid arthritis patients fulfilling Korean National Health Insurance reimbursement guidelines for anti-tumor necrosis factor-α treatment and comparison to other guidelines. | 서창희 |
| 2005 | | Rheumatoid factor is a marker of disease severity in Korean rheumatoid arthritis. | 남동호, 박해심, 서창희, 조재현 |
| 2021 | | Risk of depression, suicide and psychosis with hydroxychloroquine treatment for rheumatoid arthritis: A multinational network cohort study | 박래웅 |
| 2019 | | Rituximab biosimilar CT-P10 for the treatment of rheumatoid arthritis | 김지원, 김현아, 서창희, 정주양 |
| 2016 | | Salivary cortisol levels, but not salivary alpha-amylase levels, are elevated in patients with rheumatoid arthritis irrespective of depression | 김현아, 박샛별, 서창희 |
| 2012 | | Serum S100A8/A9, but not follistatin-like protein 1 and interleukin 18, may be a useful biomarker of disease activity in adult-onset Still's disease | 김현아, 서창희, 전자영 |
| 2020 | | Simplified disease activity changes in real-world practice: a nationwide observational study of seropositive rheumatoid arthritis patients with moderate-to-high disease activity | 서창희 |
| 2014 | | Smoking and rheumatoid arthritis. | 박세진 |
| 2017 | | Switching profiles in a population-based cohort of rheumatoid arthritis receiving biologic therapy: results from the KOBIO registry | 김현아 |
| 2012 | | The effect of smoking on response and drug survival in rheumatoid arthritis patients treated with their first anti-TNF drug: comments on the article by Söderlin et al | 박세진 |
| 2015 | | The incidence of carpal tunnel syndrome in patients with rheumatoid arthritis. | 최완선 |
| 2016 | | TLR4 Endogenous Ligand S100A8/A9 Levels in Adult-Onset Still's Disease and Their Association with Disease Activity and Clinical Manifestations | 김유선, 김현아, 서창희, 임현이, 정주양, 한재호 |
| 2017 | | Trabecular bone score as a supplementary tool for the discrimination of osteoporotic fractures in postmenopausal women with rheumatoid arthritis | 김현아, 서창희, 정윤석, 정주양, 최용준 |
| 2020 | | Trabecular Bone Score Is a Useful Parameter for the Prediction of Vertebral Fractures in Patients With Polymyalgia Rheumatica | 김현아, 서창희, 정윤석, 정주양, 최용준 |
| 2018 | | Treat-to-Target Strategy for Asian Patients with Early Rheumatoid Arthritis: Result of a Multicenter Trial in Korea | 서창희 |
| 2022 | | Two-year clinical outcomes after discontinuation of long-term golimumab therapy in Korean patients with rheumatoid arthritis | 서창희 |
| 2023 | | Unveiling difficult-to-treat rheumatoid arthritis: long-term impact of biologic or targeted synthetic DMARDs from the KOBIO registry | 김지원, 김현아, 서창희, 정주양 |
